ACRX AcelRx Pharmaceuticals Inc.

+0.02  (+1%)
Previous Close 3.38
Open 3.38
Price To Book 68
Market Cap 267776962
Shares 78,757,930
Volume 476,250
Short Ratio
Av. Daily Volume 2,327,409

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing being evaluated.
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. Penny Stocks to Buy Using Technical Analysis for April 2019
  2. AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting
  3. Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  4. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  5. AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?
  6. AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
  7. Why AcelRx Pharmaceuticals Stock Is Sinking Today
  8. Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)
  9. AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results
  10. 3 Top Small-Cap Stocks to Buy Right Now
  11. AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
  12. Biotech Leaders to Watch This Week
  13. 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
  14. Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
  15. AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
  16. Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services — Discovering Underlying Factors of Influence
  17. AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
  18. 2 Biotech Penny Stocks to Buy Right Now
  19. Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
  20. Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options